Transforming CDMO partnerships through

a holistic understanding of quality

Whitepaper

 

Quality is the underpinning of success in the pharmaceutical development and manufacturing industry.

A commitment to quality is not only required to meet regulatory guidelines, it’s also foundational to:

  • Accelerating time to market
  • Reducing unnecessary risk
  • Improving return on investment
  • Creating effective medicines
  • Ultimately saving patient lives

Despite its critical importance, quality is often mischaracterized, whether by conflating it with compliance, describing it as an end-of-the-line activity, or attributing responsibility to a single team.

In fact, quality is difficult to fully classify because it’s not defined by one single activity, role, process, strategy, or outcome. Rather, it’s a combination and culmination of all these factors — plus more.

This whitepaper takes an in-depth look at key indicators of CDMO quality, identifying tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.

Transforming CDMO partnerships through a holistic understanding of quality